- Adjusted EBITDA for Q2 2025 was $73.3 million, significantly higher than $6.8 million in Q2 2024.
- G&A expenses as a percentage of revenue decreased to 5.1% in Q2 2025 from 14% in Q2 2024, reflecting improved cost control.
- Gross profit for Q2 2025 was $124.8 million or 51.1% of total revenue, up from $22.6 million or 29.7% in Q2 2024.
- Hospital Division revenue grew 350% to $236.3 million in Q2 2025, with 71% related to independent dispute resolution (IDR) revenue.
- Net cash from operating activities was $78.2 million for the first half of 2025, compared to $16.3 million in the same period in 2024.
- Population Health Division revenue was $7.7 million in Q2 2025, down 9.2% from $8.5 million in Q2 2024 due to divestitures.
- Total patient visits increased 10.6% year-over-year to 45,573 in Q2 2025.
- Total revenue for Q2 2025 was $244 million, a 220% increase compared to $76.1 million in Q2 2024.
Related items and other data are not available for this feed item.
Dafinchi